VivoSim Labs Inc FY2025 Q3 Financial Results: Revenue Decreased 52.0%, Net Loss Narrowed to $3.45M

Executive Summary

VivoSim Labs Inc (VIVS) reported its third quarter of fiscal year 2025 with significant revenue decline and continued net losses. Revenue for Q3 2025 was $24,000, representing a 52.0% decrease compared to $50,000 in the same period last year. Despite the revenue drop, the company’s net loss narrowed to $3.45 million from $3.60 million YoY, indicating some operational improvements. Cash and cash equivalents stood at $1.16 million, with total assets of $3.84 million and total liabilities of $3.48 million. The company faces ongoing challenges but maintains a manageable liquidity position and is focusing on strategic initiatives to improve profitability.

Management Discussion and Analysis (MD&A)

VivoSim Labs continues to operate at a loss, primarily due to high R&D and administrative expenses. The revenue decline reflects reduced sales activity or market penetration issues. Operating expenses remain high at approximately $3.49 million, with R&D expenses at $1.78 million and G&A at $1.70 million. The company’s gross profit margin remains robust at 91.7%, but operating losses persist. Cash flow from operations remains negative at -$1.80 million, impacted by working capital changes and ongoing investments. Management emphasizes ongoing product development and market expansion efforts, which are expected to improve revenue streams in future periods.

Income Statement Analysis

Revenue for Q3 2025 decreased by 52.0% from $50,000 to $24,000 YoY. Gross profit remains high relative to revenue at $22,000, with a gross margin of 91.7%. Operating expenses continue to dominate, leading to an operating loss of $3.47 million, slightly improved from $3.60 million YoY. Net income from continuing operations improved marginally to a loss of $3.45 million from $3.60 million, with EPS at -2.28, reflecting ongoing challenges. The company’s revenue and net income trends highlight the need for strategic growth initiatives to reverse losses and achieve sustainable profitability.

Balance Sheet Analysis

As of December 31, 2025, VivoSim Labs reported total assets of $3.84 million, with cash and cash equivalents at $1.16 million. Total current assets are $2.10 million, primarily cash and receivables. Total liabilities stand at $3.48 million, with current liabilities at $2.94 million, including payables and accrued expenses. Total stockholders’ equity is $364,000, with a negative retained earnings balance of approximately $349 million, indicating accumulated losses. The company’s liquidity position remains stable with a net debt of -$1.01 million, suggesting a net cash position after considering debt obligations.

Cash Flow Analysis

Operating cash flow for Q3 2025 was negative at -$1.80 million, mainly due to net income losses and working capital changes. Investing activities contributed a small inflow of $4,000, primarily from investment maturities. Financing activities resulted in a net outflow of $216,000, mainly from stock repurchases. The company’s free cash flow remains negative at -$1.80 million, reflecting ongoing investments and operational challenges. Cash at period-end decreased to $1.30 million from $3.32 million in the prior year, emphasizing the need for improved cash generation strategies.

Ratios & DuPont Analysis

VivoSim Labs exhibits a net margin of -14,356%, driven by net losses. Return on assets (ROA) is approximately -89.8%, and return on equity (ROE) is about -948%, indicating significant profitability challenges. Asset turnover remains low at 0.0063, reflecting limited revenue relative to assets. The equity multiplier is approximately 10.55, indicating high leverage. These ratios underscore the company’s high risk profile but also highlight areas for operational improvement and strategic focus to enhance profitability and efficiency.

Risk Factors

The company faces several risks including regulatory hurdles in biotech development, intense market competition, operational risks related to R&D execution, and macroeconomic factors affecting funding and market demand. Financial risks include sustained losses, liquidity constraints, and high leverage. Market risks involve technological obsolescence and customer adoption rates. Management continues to monitor these factors and is implementing measures to mitigate potential adverse impacts.

Notes & Additional Commentary

VivoSim Labs’ recent financials reflect ongoing investments in R&D with no significant revenue generation yet. The company’s strategic focus remains on product development and market entry, which may result in continued losses in the near term. Unusual items include high stock-based compensation and working capital fluctuations. The company’s cash burn rate underscores the importance of securing additional funding or strategic partnerships to sustain operations and accelerate growth.

Investment Implications

While VivoSim Labs faces substantial short-term challenges with ongoing losses and limited revenue, its strong cash position and focus on innovation could position it for future growth if product development milestones are achieved. Investors should consider the high risk associated with early-stage biotech companies but also recognize the potential for upside if commercialization efforts s쳮d. A balanced approach involves monitoring operational progress, funding strategies, and market developments to assess long-term viability.